Amylin (Islet amyloid polypeptide, AIPP(34-70)) is a 37-residue peptide hormone which belongs to the calcitonin peptide family. It is cosecreted with insulin from pancreatic β-cells and plays a role in glycemic regulation by preventing post-prandial spikes in blood glucose levels. Its effects are mediated via binding to three distinct receptor complexes containing the calcitonin receptor, plus one of three receptor activity-modifying proteins, RAMP1, RAMP2, or RAMP3.

Pramlintide is a synthetic analogue of human amylin with proline substitutions in positions 25, 26 and 29. Its actions are mediated through calcitonin-RAMP receptor complexes (Gingell et al. 2014). Pramlintide is approved for use in patients with both diabetes mellitus type 1 and diabetes mellitus type 2 (Schmitz et al. 1997, Edelman et al. 2008). Structure-function relationships of amylin are being used for the development of newer amylin mimetic drug (Bower & Hay 2016).